Close

Wall Street Expecting Delays to Antitrust Clearance for Cephalon/Teva Deal (CEPH) (TEVA)

May 16, 2011 2:27 PM EDT
DealReporter is saying the potential deal between Cephalon (Nasdaq: CEPH) and Teva (Nasdaq: TEVA) may take longer-than-expected to get antitrust clearance as the transaction would include a number of reverse settlements.

Specifically, DealReporter's sources say Cephalon and Teva have been "singled out" due to their "pay-for-delay" practices.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Rumors